Introduction: Addressing the Asian Paradox in Obesity
Obesity is a global health crisis, but its clinical manifestation and associated risks vary significantly across ethnic populations. In many Asian regions, individuals experience increased metabolic health risks—such as type 2 diabetes and cardiovascular disease—at much lower body mass index (BMI) levels compared to Western populations. Consequently, the World Health Organization (WHO) and local health authorities in countries like South Korea and Thailand define obesity starting at a BMI of 25 kg/m2. While the efficacy of the GLP-1 receptor agonist semaglutide 2.4 mg has been well-established in global trials (the STEP program), there remained a critical need for high-quality, randomized controlled data specifically targeting this Asian demographic at these lower BMI thresholds. The STEP 11 trial was designed to bridge this gap.
